99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer
Phase 3
Completed
- Conditions
- Lung CancerLymph Node Metastasis
- Interventions
- Drug: 99mTc-3PRGD2 injection
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- RDO Pharm.
- Target Recruit Count
- 409
- Registration Number
- NCT04233476
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- RDO Pharm.
- Target Recruit Count
- 10
- Registration Number
- NCT03974685
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath